Endo Pharmaceuticals Sees 2011 EPS of $4.20 and $4.30

Endo ENDP now estimates 2011 revenues to be between $2.35 billion and $2.45 billion, reported (GAAP) diluted earnings per share to be between $2.43 and $2.53 and adjusted diluted earnings per share to be between $4.20 and $4.30.